15159-14-5

Usage

Uses

Used in Pharmaceutical Research:
6-Methoxy-5-methyl-3,4-dihydro-2H-naphthalen-1-one is used as a research compound for inducing cytochrome P450 enzymes, which are essential in the metabolism and detoxification of drugs and environmental chemicals in the body.
Used in Antioxidant and Anti-inflammatory Applications:
6-Methoxy-5-methyl-3,4-dihydro-2H-naphthalen-1-one is used as a potential antioxidant and anti-inflammatory agent due to its ability to modulate the expression of genes involved in drug metabolism and carcinogen activation.
Used in Cancer Treatment Research:
6-Methoxy-5-methyl-3,4-dihydro-2H-naphthalen-1-one is used as a potential cancer treatment agent, as it may have the ability to inhibit the growth of certain cancer cells.

Upstream product

• 211503-45-6 4-(3-methoxy-2-methylphenyl)butanoic acid 
• 806607-37-4 2-(2-Methoxy-5-oxo-5,6,7,8-tetrahydro-naphthalen-1-ylmethyl)-isothiourea 
• 1758-21-0 6-methoxy-5-methyltetralene 
• 64-19-7 acetic acid 
• 64-17-5 ethanol 
• 105372-29-0 2,5-dimethoxy-1-methylnaphthalene 
• 32260-73-4 7-methoxy-8-methyl-α-tetralone 
• 32260-72-3 6-Brom-7-methoxy-8-methyl-1-tetralon 
• 33446-15-0 4-(4-methoxy-3-methylphenyl)butyric acid 
• 1076-26-2 1-methyl-2-naphthol 
• 56771-15-4 1-methyl-5,6,7,8-tetrahydro-2-naphthol 
• 860537-09-3 2-chloro-1-(3-methoxy-2-methyl-phenyl)-ethanone 
• 92576-46-0 6-Methoxy-5-chlormethyl-tetralon-⁽¹⁾ 
• 109128-46-3 2-(2-Methoxy-5-oxo-5,6,7,8-tetrahydro-naphthalen-1-ylmethyl)-isothiourea; hydrochloride 

Downstream Products

• 56771-15-4 1-methyl-5,6,7,8-tetrahydro-2-naphthol 
• 109397-32-2 6-methoxy-5-methyl-3,4-dihydro-2H-naphthalen-1-one-(2,4-dinitro-phenylhydrazone) 

Relevant academic research and scientific papers

Alternative route for the synthesis of 6-methoxy-5-methyl-α-tetralone and 6-methoxy-2,5-dimethyl-α-tetralone

The ketoesters 3 and 4, obtained by the condensation of 2-cyclohexanone carboxylate and 1-chloro-3-pentanone, were heated with 2,3-dichloro-5,6- dicyanobenzoquinone (DDQ) to yield the dienones 5 and 6, which on hydrolysis with potassium t-butoxide and dimethyl sulfoxide afforded tetralin 8. These were converted to tetralone 10 by methylation and oxidation respectively. Further methylation of 10 yielded tetralone 11. Copyright Taylor & Francis Group, LLC.

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases

The discovery of 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 13n (ceralifimod, ONO-4641), a sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5, is described. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases such as relapsing-remitting multiple sclerosis (RRMS), it was also reported that activation of the S1P3 receptor is implicated in some undesirable effects. We carried out a structure-activity relationship (SAR) study of hit compound 6 with an amino acid moiety in the hydrophilic head region. Following identification of a lead compound with a dihydronaphthalene central core by inducing conformational constraint, optimization of the lipophilic tail region led to the discovery of 13n as a clinical candidate that exhibited >30 000-fold selectivity for S1P1 over S1P3 and was potent in a peripheral lymphocyte lowering (PLL) test in mice (ED50 = 0.029 mg/kg, 24 h after oral dosing).

SYNTHESIS OF BRIDGED CARBOCYCLIC SYSTEMS RELATED TO DITERPENES INVOLVING INTRAMOLECULAR CYCLISATION OF DIAZOMETHYL KETONES

The tricyclic dienediones 5, 6 and 7 have been synthesised for entry into the ring systems of the tetracyclic diterpenes atisirene (1), phyllocladene (3) and hibaene (4) respectively.